Quest for the right Drug

|
עמוד הבית / קסנאקס אקס.אר. 2 מ"ג / מידע מעלון לרופא

קסנאקס אקס.אר. 2 מ"ג XANAX X.R. 2 MG (ALPRAZOLAM)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליות עם שחרור מושהה : TABLETS SUSTAINED RELEASE

Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

12.1 Mechanism of Action
Alprazolam is a 1,4 benzodiazepine. Alprazolam exerts its effect for the treatment of panic disorder through binding to the benzodiazepine site of gamma aminobutyric acid-A (GABAA) receptors in the brain and enhances GABA-mediated synaptic inhibition.

Pharmacokinetic Properties

12.2 Pharmacokinetics

The pharmacokinetics of alprazolam and two of its major active metabolites (4- hydroxyalprazolam and α-hydroxyalprazolam) are linear, and concentrations are proportional up to 10 mg XANAX XR given once daily.

Absorption
Following oral administration of XANAX XR in the morning, peak plasma concentration of alprazolam (Cmax) occurs in about 10 hours postdose. Compared to morning dosing, alprazolam Cmax increased by 30% and the Tmax decreased by an hour following dosing at night.

The mean absolute bioavailability of alprazolam following administration of XANAX XR is approximately 90%, and the relative bioavailability compared to XANAX is about 100%.
The bioavailability and pharmacokinetics of alprazolam following administration of XANAX XR are similar to that for XANAX, with the exception of a slower rate of absorption.

Effect of Food
A high-fat meal given up to 2 hours before dosing with XANAX XR increased the mean Cmax by about 25%. The effect of this meal on Tmax depended on the timing of the meal, with a reduction in Tmax by about 1/3 for subjects eating immediately before dosing and an increase in Tmax by about 1/3 for subjects eating 1 hour or more after dosing. The extent of exposure (AUC) and elimination half-life (t½) were not affected by eating.

Distribution
The apparent volume of distribution of alprazolam is similar for XANAX XR and XANAX.
Alprazolam is 80% bound to human serum protein, and albumin accounts for the majority of the binding.

Elimination
The mean plasma elimination half-life of alprazolam following administration of XANAX XR ranges from 10.7 to 15.8 hours in healthy adults.

Metabolism
Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major active metabolites in the plasma: 4-hydroxyalprazolam and α- hydroxyalprazolam. The plasma circulation levels of the two active metabolites after both Xanax XR and Xanax are less than 10% and 4% of the parent, respectively. The reported relative potencies in benzodiazepine receptor binding experiments and in animal models of induced seizure inhibition are 0.20 and 0.66, respectively, for 4-hydroxyalprazolam and α- hydroxyalprazolam. The low concentrations and low potencies of 4-hydroxyalprazolam and α-hydroxyalprazolam indicate that they unlikely contribute much to the effects of alprazolam. A benzophenone derived from alprazolam is also found in humans. Their half- lives appear to be similar to that of alprazolam. The pharmacokinetic parameters at steady- state for the two hydroxylated metabolites of alprazolam (4-hydroxyalprazolam and α-hydroxyalprazolam) were similar for XANAX and XANAX XR, indicating that the metabolism of alprazolam is not affected by absorption rate.

Excretion
Alprazolam and its metabolites are excreted primarily in the urine.

Specific Populations
Geriatric Patients
The mean T1/2 of alprazolam was 16.3 hours (range: 9.0 to 26.9 hours) in healthy elderly subjects compared to 11.0 hours (range: 6.3 to 15.8 hours, n=16) in healthy adult subjects.

Obese Patients
The mean T1/2 of alprazolam was 21.8 hours (range: 9.9 to 40.4 hours) in a group of obese subjects.

Patients with Hepatic Impairment
The mean T1/2 of alprazolam was 19.7 hours (range: 5.8 to 65.3 hours) in patients with alcoholic liver disease.

Racial or Ethnic Groups
Maximal concentrations and T1/2 of alprazolam are approximately 15% and 25% higher in Asians compared to Caucasians.

Smoking
Alprazolam concentrations may be reduced by up to 50% in smokers compared to non- smokers.

Drug Interaction Studies

In Vivo Studies
Most of the interactions that have been documented with alprazolam are with drugs that modulate CYP3A4 activity.

Compounds that are inhibitors or inducers of CYP3A would be expected to increase or decrease plasma alprazolam concentrations, respectively. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98-fold; itraconazole, 2.66 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold [see Contraindications (4), Warnings and Precautions (5.5), Drug Interactions (7.1)]. Other studied drugs include:

Cimetidine: Coadministration of cimetidine increased the maximum plasma concentration of alprazolam by 82%, decreased clearance by 42%, and increased T1/2 by 16%.

Fluoxetine: Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased T1/2 by 17%, and decreased measured psychomotor performance.

Oral Contraceptives: Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased T1/2 by 29%.

Carbamazepine: The oral clearance of alprazolam (given in a 0.8 mg single dose) was increased from 0.90±0.21 mL/min/kg to 2.13±0.54 mL/min/kg and the elimination T1/2 was shortened (from 17.1±4.9 to 7.7 ±1.7 hour) following administration of 300 mg per day carbamazepine for 10 days [see Drug Interactions (7.1)]. However, the carbamazepine dose used in this study was fairly low compared to the recommended doses (1000-1200 mg per day); the effect at usual carbamazepine doses is unknown.

Ritonavir: Interactions involving HIV protease inhibitors (eg, ritonavir) and alprazolam are complex and time dependent. Short-term low doses of ritonavir (4 doses of 200 mg) increased mean AUC of alprazolam by about 2.5-fold and did not significantly affect Cmax of alprazolam. The elimination T1/2 was prolonged (30 hours versus 13 hours).
However, upon extended exposure to ritonavir (500 mg, twice daily for 10 days), CYP3A induction offset this inhibition. Alprazolam AUC and Cmax was reduced by 12% and 16%, respectively, in the presence of ritonavir. The elimination T1/2 of alprazolam was not significantly changed [see Warnings and Precautions (5.5)].

Sertraline: A single dose of alprazolam 1 mg and steady state dose of sertraline (50 to 150 mg per day) did not reveal any clinically significant changes in the pharmacokinetics of alprazolam.

Imipramine and Desipramine: The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of XANAX in doses up to 4 mg per day.

Warfarin: Alprazolam did not affect the prothrombin or plasma warfarin levels in male volunteers administered sodium warfarin orally.

In Vitro Studies
Data from in vitro studies of alprazolam suggest a possible drug interaction of alprazolam with paroxetine. The ability of alprazolam to induce human hepatic enzyme systems has not been determined.
שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

בעל רישום

DEXCEL LTD, ISRAEL

רישום

110 51 28806 21

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

01.03.17 - עלון לרופא 18.07.21 - עלון לרופא 05.06.23 - עלון לרופא 02.06.24 - עלון לרופא

עלון מידע לצרכן

22.02.22 - עלון לצרכן אנגלית 22.02.22 - עלון לצרכן עברית 22.02.22 - עלון לצרכן ערבית 05.06.23 - עלון לצרכן עברית 04.12.11 - החמרה לעלון 29.12.11 - החמרה לעלון 29.12.11 - החמרה לעלון 17.06.14 - החמרה לעלון 18.07.21 - החמרה לעלון 26.09.21 - החמרה לעלון 22.02.22 - החמרה לעלון 05.06.23 - החמרה לעלון

לתרופה במאגר משרד הבריאות

קסנאקס אקס.אר. 2 מ"ג

קישורים נוספים

RxList WebMD Drugs.com